美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Therapeutics

3.61

-0.0350-0.96%

盘后：3.650.0400+1.11%19:30 EDT

成交量：60.35万

成交额：220.14万

市值：1.13亿

市盈率：-0.87

高：3.71

开：3.64

低：3.60

收：3.65

52周最高：46.75

52周最低：3.35

股本：3,129.00万

流通股本：1,839.33万

量比：0.83

换手率：3.28%

股息：- -

股息率：- -

每股收益(TTM):-4.1300

每股收益(LYR):-2.8503

净资产收益率：-59.21%

总资产收益率：-37.36%

市净率：0.52

市盈率(LYR):-1.27

数据加载中...

总览公司新闻资讯公告

Lenz Therapeutics推出新型远程医疗处方方案，加速老花眼患者获取Vizz®治疗

生物技术公司Scribe Therapeutics(SCTX.US)申请美股IPO 拟筹资至多7500万美元

联合治疗公司以1.4亿美元现金收购生物技术公司Thymmune Therapeutics。

Stoke Therapeutics完成Dravet综合征药物关键III期试验患者入组

环球市场播报

Unicycive Therapeutics股价下跌45.8%，此前美国食品药品监督管理局拒绝批准该公司的肾病药物。

新闻稿：Akari Therapeutics 完成先前宣布的PIPE融资，强化资产负债表以迎接关键临床与监管里程碑

新闻稿：Rani Therapeutics任命尼古拉斯·马埃斯塔斯为首席财务官

益普生将以最高17.5亿美元收购Kartos Therapeutics

分析-2025年，随着高价基因疗法上市数量减少，美国新药价格出现下降

Lenz Therapeutics与Arrotex Pharmaceuticals就Vizz™在澳大利亚和新西兰达成独家许可与商业化协议

Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价每股34美元

新股消息 | Frontera Therapeutics港股IPO招股书失效

德琪医药-B(06996)与MPM BioImpact创立的K2 Therapeutics就ATG-106达成独家授权协议并授予其一项未披露双特异性TCE的选择权

Viking Therapeutics任命Hubert C. Chen博士为新任首席医疗官

环球市场播报

Silence Therapeutics公布divesiran随访数据，展现持久疗效和同类最佳潜力

环球市场播报

Lenz宣布与云顶新耀达成协议，后者获Vizz®(Lnz100)大中华区开发及商业化权益

Ovid Therapeutics 任命顶尖医师科学家兼生物技术创新者 Anna Greka 博士加入董事会

Kazia Therapeutics任命资深交易专家James Levine为新任CFO

环球市场播报

Vector Science & Therapeutics授出20.6万份期权持续推进增长战略

环球市场播报

Decoy Therapeutics携手hVIVO，推进首创多靶点抗病毒药物D-MAV进入临床

环球市场播报

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/LENZ/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":3.61,"timestamp":1791835200000,"preClose":3.645,"halted":0,"volume":603478,"hourTrading":{"tag":"盘后","latestPrice":3.65,"preClose":3.61,"latestTime":"19:30 EDT","volume":8261,"amount":29830.46,"timestamp":1791847801709,"change":0.04,"changeRate":0.01108,"amplitude":0.01108},"delay":0,"changeRate":-0.009602194787380012,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"未开盘","change":-0.035,"latestTime":"10-12 16:00:00 EDT","open":3.64,"high":3.71,"low":3.6,"amount":2201377.548917,"amplitude":0.030178,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791878400000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.645,"preHourTrading":{"tag":"盘前","latestPrice":3.5741,"preClose":3.645,"latestTime":"08:41 EDT","volume":249,"amount":915.154132,"timestamp":1791808899894,"change":-0.0709,"changeRate":-0.019451,"amplitude":0.065844},"postHourTrading":{"tag":"盘后","latestPrice":3.65,"preClose":3.61,"latestTime":"19:30 EDT","volume":8261,"amount":29830.46,"timestamp":1791847801709,"change":0.04,"changeRate":0.01108,"amplitude":0.01108},"volumeRatio":0.82928,"impliedVol":2.4768,"impliedVolPercentile":0.8406},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":0.82928,"shares":31289969,"dividePrice":0,"high":3.71,"amplitude":0.030178,"preClose":3.645,"low":3.6,"week52Low":3.35,"pbRate":"0.52","psRate":"5.26","week52High":46.75,"institutionHeld":0,"latestPrice":3.61,"eps":-4.13,"divideRate":0,"volume":603478,"delay":0,"ttmEps":-4.13,"open":3.64,"prevYearClose":16,"prevWeekClose":3.645,"prevMonthClose":3.84,"prevQuarterClose":3.84,"fiveDayClose":3.59,"twentyDayClose":4.47,"sixtyDayClose":5.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"盘后","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"盘后","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"盘前","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"盘前","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-10-09","current":-0.874092,"percent":1,"low":-26.69966,"twenty":-16.189658,"median":-9.502762,"eighty":-3.671954,"high":-0.880254,"avg":-10.19642,"sd":6.330004,"marketCap":110913810},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849},{"date":"2026-09-04","current":-1.453791,"twenty":-16.251993,"median":-9.763078,"eighty":-5.336455,"marketCap":183180599},{"date":"2026-09-11","current":-1.176997,"twenty":-16.223282,"median":-9.734689,"eighty":-5.236314,"marketCap":148304018},{"date":"2026-09-18","current":-1.029873,"twenty":-16.218091,"median":-9.676907,"eighty":-3.875061,"marketCap":129766016},{"date":"2026-09-25","current":-0.927633,"twenty":-16.212803,"median":-9.639455,"eighty":-3.772744,"marketCap":116883675},{"date":"2026-10-02","current":-0.945089,"twenty":-16.204574,"median":-9.574004,"eighty":-3.700206,"marketCap":119083099},{"date":"2026-10-09","current":-0.880254,"twenty":-16.189658,"median":-9.502762,"eighty":-3.671954,"marketCap":110913810}],"updateTime":1791864709465},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1183410479","title":"Lenz Therapeutics推出新型远程医疗处方方案，加速老花眼患者获取Vizz®治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1183410479","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183410479?lang=zh_cn&edition=fundamental","pubTime":"2026-07-06 20:22","pubTimestamp":1783340531,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics宣布推出一种新型远程医疗处方方案，旨在加速老花眼患者获取Vizz®治疗。此举将简化患者的治疗流程，提高治疗的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649197641","title":"生物技术公司Scribe Therapeutics(SCTX.US)申请美股IPO 拟筹资至多7500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649197641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649197641?lang=zh_cn&edition=fundamental","pubTime":"2026-07-06 15:30","pubTimestamp":1783323045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FRHC","WDNA","BK4139","KCE","BK4539","LENZ","IPOS","BK4007","BK4127","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648509782","title":"联合治疗公司以1.4亿美元现金收购生物技术公司Thymmune Therapeutics。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648509782","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648509782?lang=zh_cn&edition=fundamental","pubTime":"2026-07-02 18:31","pubTimestamp":1782988300,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647551730","title":"Stoke Therapeutics完成Dravet综合征药物关键III期试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2647551730","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647551730?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 21:47","pubTimestamp":1782827220,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics近日宣布，其针对Dravet综合征的潜在疾病修饰疗法zorevunersen的全球III期EMPEROR研究已完成全部162名患者的入组工作。这一里程碑的达成，标志着该药物向提交新药申请、尽快惠及患者迈出了关键一步。　　此前，公司预计将在2026年第二季度完成约150名患者的入组。此次公布的162名患者入组数量超出了这一预期。　　Zorevunersen是一款首创的反义寡核苷酸药物，旨在通过增加脑细胞中非突变SCN1A基因拷贝的功能性NaV1.1蛋白表达，从根本上治疗Dravet综合征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-iniffcps6559776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4539","BK4139","BK4134","III","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647455165","title":"Unicycive Therapeutics股价下跌45.8%，此前美国食品药品监督管理局拒绝批准该公司的肾病药物。","url":"https://stock-news.laohu8.com/highlight/detail?id=2647455165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647455165?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 21:31","pubTimestamp":1782826311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4139","UNCY","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132616293","title":"新闻稿：Akari Therapeutics 完成先前宣布的PIPE融资，强化资产负债表以迎接关键临床与监管里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1132616293","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132616293?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 20:47","pubTimestamp":1782737248,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC  是一家专注于开发搭载新型RNA剪接调节剂有效载荷的抗体药物偶联物的肿瘤学生物技术公司。该公司近日宣布，已通过将剩余计划投资交割合并为单一融资事件，完成了先前公布的私募股权投资。结合五月份完成的认股权证行权，公司在2026年第二季度总计获得了约830万美元资本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTX","BK4007","BK4539","PIPE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146816793","title":"新闻稿：Rani Therapeutics任命尼古拉斯·马埃斯塔斯为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1146816793","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146816793?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 20:02","pubTimestamp":1782734563,"startTime":"0","endTime":"0","summary":"临床阶段生物治疗公司Rani Therapeutics Holdings, Inc.今日宣布，任命尼古拉斯·马埃斯塔斯为首席财务官，即刻生效。Rani Therapeutics首席执行官塔拉特·伊姆兰表示：“我们很高兴欢迎尼古拉斯担任我们的新任首席财务官。他在生物制药资本市场和企业战略方面的深厚经验，使其非常适合引领Rani进入下一个发展阶段。同时，我们也要再次感谢斯瓦伊·桑福德多年来的稳健领导及其为保障平稳交接所做的承诺。”","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4539","BK4139","R","LENZ","BK4022","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647232807","title":"益普生将以最高17.5亿美元收购Kartos Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2647232807","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647232807?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 13:20","pubTimestamp":1782710416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646794508","title":"分析-2025年，随着高价基因疗法上市数量减少，美国新药价格出现下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2646794508","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646794508?lang=zh_cn&edition=fundamental","pubTime":"2026-06-25 18:01","pubTimestamp":1782381707,"startTime":"0","endTime":"0","summary":"分析-2025年，随着高价基因疗法上市数量减少，美国新药价格出现下降2025年获FDA批准的药品年均标价中位数为216,000美元2025年，FDA批准了51种新药，其中包括5种细胞和基因疗法2025年获批药物中，小分子药物占比超过67%，高于2024年的62%Deena Beasley路透6月25日-一项最新分析显示，2025年美国监管机构批准的处方药上市价格虽较上年有所下降，但受罕见病高价药物影响，中位数仍高达216,000美元。基因疗法通常只需给药一次，其价格可能高达数百万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nL4S42X0VU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK4585","BK4539","BK4588","LENZ","IONS","IE00BN0W2T93.GBP","BK4533","BK4139","ALNY","BK4007","LU0320765992.SGD","BK4548","LU0889565916.HKD","BK4532","IE00BN0W2W23.USD","LU0154245756.USD","BK7501","LU0882574055.USD","ABEO","BK7511","LU0823416689.USD","LU0154245673.USD","IE00BN0W2V16.EUR","BK7067","NTI.AU","BK7007","JAZZ","BK7508","LU0109394709.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158361816","title":"Lenz Therapeutics与Arrotex Pharmaceuticals就Vizz™在澳大利亚和新西兰达成独家许可与商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1158361816","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158361816?lang=zh_cn&edition=fundamental","pubTime":"2026-06-24 20:32","pubTimestamp":1782304365,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics与Arrotex Pharmaceuticals宣布，双方已就Vizz™在澳大利亚和新西兰市场达成一项独家许可与商业化合作协议。该协议的签署标志着两家公司将在上述区域共同推进Vizz™的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645889615","title":"Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价 每股34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645889615","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645889615?lang=zh_cn&edition=fundamental","pubTime":"2026-06-24 17:11","pubTimestamp":1782292315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 临床后期生物制药公司Definium Therapeutics 正式宣布，其已完成扩大规模的包销公开发行定价，公司将以每股34.00美元的价格公开发行20,588,236股普通股。在不扣除承销折扣、佣金及其他发行费用的情况下，Definium预计此次公开发行的募资总额将达到约7亿美元。本次发行预计将于2026年6月25日左右交割。而就在本次发行定价前不久，Definium刚于6月22日宣布，其用于治疗重度抑郁症的创新疗法“DT120口崩片”在3期临床研究中取得了积极的顶线结果。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","UUP","LENZ","UDN","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645005284","title":"新股消息 | Frontera Therapeutics港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2645005284","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645005284?lang=zh_cn&edition=fundamental","pubTime":"2026-06-23 07:23","pubTimestamp":1782170623,"startTime":"0","endTime":"0","summary":"据招股书显示，自2019年成立以来，Frontera Therapeutics一直致力于自主开发创新的重组腺相关病毒基因疗法。Frontera Therapeutics已构建一个敏捷且协调良好的研发团队。通过与领先医院及研究机构合作，Frontera Therapeutics已能够实现高效的中心启动及方案部署。迄今为止，Frontera Therapeutics已获得国家药监局和FDA的12项IND批准，根据弗若斯特沙利文的资料，成为中国获得IND批准数量最多的rAAV基因疗法开发公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","BK4007","VXUS","BK4585","LENZ","BK4588","IPOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645685014","title":"德琪医药-B(06996)与MPM BioImpact创立的K2 Therapeutics就ATG-106达成独家授权协议 并授予其一项未披露双特异性TCE的选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2645685014","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645685014?lang=zh_cn&edition=fundamental","pubTime":"2026-06-22 08:36","pubTimestamp":1782088596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，Antengene Biologics Limited与由K2 Therapeutics新成立的一家公司， 已就ATG-106订立一份独家且可再授权的授权协议。此外， K2与授权方亦已订立一份选择权协议，据此，K2已获授一项独家选择权，以取得一款未披露的临床前双特异性TCE候选药物的独家授权。MPM BioImpact是一家全球领先的生物技术投资机构，拥有逾30年创建及投资创新公司的经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","06996","BK4139","BK1583","BK4007","BK1191","BK4539","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642382782","title":"Viking Therapeutics任命Hubert C. Chen博士为新任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=2642382782","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642382782?lang=zh_cn&edition=fundamental","pubTime":"2026-06-11 23:06","pubTimestamp":1781190360,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Viking Therapeutics周四宣布，任命Hubert C． Chen博士为首席医疗官。Chen博士将负责领导公司的临床开发、医学及监管事务，直接向公司总裁兼首席执行官Brian Lian博士汇报。在加入Viking之前，他曾担任Loyal Animal Health的首席研发官，领导了首个与美国食品药品监督管理局达成谈判的长寿疗法有效性和安全性要求制定工作。　　这一任命正值Viking推进其核心候选药物VK2735的关键时期。Viking还计划于本季度启动新型胰淀素激动剂VK3019的一期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0642884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4007","BK4539","BK4139","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280749","title":"Silence Therapeutics公布divesiran随访数据，展现持久疗效和同类最佳潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280749","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280749?lang=zh_cn&edition=fundamental","pubTime":"2026-06-11 22:27","pubTimestamp":1781188020,"startTime":"0","endTime":"0","summary":"Silence Therapeutics本周在2026年欧洲血液学协会年会上公布了其在研siRNA疗法divesiran的1期SANRECO研究最新随访数据。数据显示，该药物在真性红细胞增多症患者中表现出持久的疗效，停药后仍可维持对红细胞压积的控制，并显著改善疾病相关症状和生活质量。　　Silence Therapeutics首席医学官Curtis Rambaran博士表示，在1期研究中观察到持续的红细胞压积控制、症状改善以及放血负担的显著且持久的减少，这些发现进一步支持了低频给药的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0622536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169652203","title":"Lenz宣布与云顶新耀达成协议，后者获Vizz®(Lnz100)大中华区开发及商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1169652203","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169652203?lang=zh_cn&edition=fundamental","pubTime":"2026-06-08 07:31","pubTimestamp":1780875098,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics公司宣布，已与Everest Medicines（云顶新耀）达成授权协议。根据协议，云顶新耀获得了在大中华区（包括中国大陆、香港、澳门及台湾）开发和商业化Vizz®（研发代号Lnz100）的独家权利。\n该交易标志着Lenz的核心产品管线进入了重要的亚太市场。Vizz®（Lnz100）是一款处于研发阶段的创新疗法，此次合作将加速该产品在广阔的大中华区的临床开发与未来市场准入。\n通过此次授权，Lenz有望获得包括首付款、里程碑付款以及基于未来销售额的特许权使用费在内的潜在收益。云顶新耀则将凭借其在本地区的开发与商业化能力，推动该产品的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196834201","title":"Ovid Therapeutics 任命顶尖医师科学家兼生物技术创新者 Anna Greka 博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1196834201","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196834201?lang=zh_cn&edition=fundamental","pubTime":"2026-06-03 19:02","pubTimestamp":1780484529,"startTime":"0","endTime":"0","summary":"致力于为存在重大未满足需求的脑部疾病研发更优、更温和药物的生物制药公司 Ovid Therapeutics Inc.  今日宣布，任命安娜·格雷卡医学及哲学博士加入其董事会，自2026年6月15日起生效。自2026年6月15日起，格雷卡博士将担任 Ovid 新成立的科学与技术委员会主席，并担任薪酬委员会成员。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OVID","BK4588","BK4581","LENZ","IS","BK4585","BK4139","BK4007","XBI","BK4097","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640594153","title":"Kazia Therapeutics任命资深交易专家James Levine为新任CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640594153","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640594153?lang=zh_cn&edition=fundamental","pubTime":"2026-06-02 22:48","pubTimestamp":1780411680,"startTime":"0","endTime":"0","summary":"澳大利亚临床阶段肿瘤公司Kazia Therapeutics Limited宣布，任命James Levine为首席财务官，自2026年6月1日起生效。Levine拥有超过二十年的投资银行及生物技术公司高管经验，曾在高盛担任董事总经理，并领导过总计数十亿美元的生物医药交易。　　Levine近期担任Cardiff Oncology首席财务官，此前曾任Cidara Therapeutics首席财务官，主导了与Mundipharma及强生旗下Janssen Pharmaceuticals的财务架构设计。　　Kazia的核心资产paxalisib是一款口服、可入脑的PI3K/mTOR双重抑制剂，正在开发用于多种癌症。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumh2971166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640492479","title":"Vector Science & Therapeutics授出20.6万份期权 持续推进增长战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492479","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640492479?lang=zh_cn&edition=fundamental","pubTime":"2026-06-02 22:39","pubTimestamp":1780411140,"startTime":"0","endTime":"0","summary":"Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。此次期权授予尚需获得多伦多证券交易所创业板的批准。　　公司于今年4月完成在多伦多证券交易所创业板的上市，股票代码PAIN，为这一增长战略的推进提供了资本市场支持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumk4647843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4139","BK4007","VAQC","BK4561","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968665","title":"Decoy Therapeutics携手hVIVO，推进首创多靶点抗病毒药物D-MAV进入临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968665","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968665?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 23:01","pubTimestamp":1780326089,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics今日宣布，已与全球人类挑战研究领域的领先企业hVIVO达成战略合作，旨在将其首创的“可设计多靶点抗病毒药物”候选物推进至临床阶段。　　Decoy首席执行官Rick Pierce表示：“病毒性疾病不应每次都需要一种新药。我们与hVIVO的合作是将这一创新疗法在人体中进行验证的关键一步。”　　此次合作标志着Decoy Therapeutics从临床前阶段向临床阶段公司的关键转型。公司计划在未来两年内为其泛冠状病毒项目和三联项目提交两项新药临床试验申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxmem2285401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["MAV","BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":106,"code":"91000000","status":"200"}]}}